Neuropeptides
Volume 44, Issue 5 , Pages 421-429, October 2010

Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats

  • Svetlana Semenova

      Affiliations

    • Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Psychiatry, School of Medicine, University of California San Diego, 9500 Gilman Drive, M/C 0603, La Jolla, CA 92093-0603, USA. Tel.: +1 (858) 534 1528; fax: +1 (858) 858 534 9917.
  • ,
  • Daniel Hoyer

      Affiliations

    • Psychiatry/Neuroscience Research, Novartis Institute for Biomedical Research, CH 4002 Basel, Switzerland
  • ,
  • Mark A. Geyer

      Affiliations

    • Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA
  • ,
  • Athina Markou

      Affiliations

    • Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA

Received 11 December 2009; accepted 29 April 2010. published online 01 June 2010.

Abstract 

Somatostatins have been shown to be involved in the pathophysiology of motor and affective disorders, as well as psychiatric disorders, including schizophrenia. We hypothesized that in addition to motor function, somatostatin may be involved in somatosensory gating and reward processes that have been shown to be dysregulated in schizophrenia. Accordingly, we evaluated the effects of intracerebroventricular administration of somatostatin-28 on spontaneous locomotor and exploratory behavior measured in a behavioral pattern monitor, sensorimotor gating, prepulse inhibition (PPI) of the acoustic startle reflex, and brain reward function (measured in a discrete trial intracranial self-stimulation procedure) in rats. Somatostatin-28 decreased spontaneous locomotor activity during the first 10min of a 60min testing session with no apparent changes in the exploratory activity of rats. The highest somatostatin-28 dose (10μg/5μl/side) induced PPI deficits with no effect on the acoustic startle response or startle response habituation. The somatostatin-induced PPI deficit was partially reversed by administration of SRA-880, a selective somatostatin 1 (sst1) receptor antagonist. Somatostatin-28 also induced elevations in brain reward thresholds, reflecting an anhedonic-like state. The non-peptide sst1 receptor antagonist SRA-880 had no effect on brain reward function under baseline conditions. Altogether these findings suggest that somatostatin-28 modulates PPI and brain reward function but does not have a robust effect on spontaneous exploratory activity. Thus, increases in somatostatin transmission may represent one of the neurochemical mechanisms underlying anhedonia, one of the negative symptoms of schizophrenia, and sensorimotor gating deficits associated with cognitive impairments in schizophrenia patients.

Keywords: Sensorimotor gating, Intracranial self-stimulation, Reward thresholds, Anhedonia, Schizophrenia, SRA-880

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0143-4179(10)00049-1

doi:10.1016/j.npep.2010.04.008

Neuropeptides
Volume 44, Issue 5 , Pages 421-429, October 2010